Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.38 |
| ▸ | NMT1 | P30419 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30412108 | 1.00 | GPR35 (0.38) | GPR35NMT1ALDH1A1MAPTCA1 | |
| SCHEMBL21225138 | 0.78 | GPR35 (0.32) | GPR35NMT1ALDH1A1MAPTCA1 | |
| Hydrochloric Acid SCHEMBL21225609 | 0.77 | GPR35 (0.32) | GPR35NMT1ALDH1A1MAPTCA1 | |
| SCHEMBL2139027 | 0.76 | ALDH1A1 (0.52) | ALDH1A1MAPTCA1CA2CA9 | |
| Hydrochloric Acid SCHEMBL20984782 | 0.74 | ALDH1A1 (0.50) | ALDH1A1MAPTCA1CA2CA9 | |
| Bromide SCHEMBL20984420 | 0.74 | ALDH1A1 (0.50) | ALDH1A1MAPTCA1CA2CA9 | |
| SCHEMBL10872330 | 0.74 | ALDH1A1 (0.53) | GPR35NMT1ALDH1A1CYP3A4 | |
| SCHEMBL9212429 | 0.73 | NMT1 (0.38) | NMT1 | |
| SCHEMBL10982842 | 0.73 | CYP3A4 (0.50) | ALDH1A1MAPTCA1CA2CA9 | |
| SCHEMBL1997699 | 0.73 | CA1 (0.50) | ALDH1A1MAPTCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179079-A1 | HEXAHYDROPYRIDO[4,3-B]INDOLYL KETONE DERIVATIVES USEFUL AS CGAS MODULATORS | VENTUS THERAPEUTICS U.S., INC. (US) | 2025-06-05 | — | — | US | disclosed |
| EP-4496796-A1 | HEXAHYDROPYRIDO[4,3-B]INDOLYL KETONE DERIVATIVES USEFUL AS CGAS MODULATORS | Ventus Therapeutics U.S., Inc. (US) | 2025-01-29 | — | — | EP | disclosed |
| US-20240246979-A1 | cGAS INHIBITORS | ELI LILLY AND COMPANY | 2024-07-25 | — | — | US | disclosed |
| WO-2024137752-A1 | AZEPINO[4,5-B]INDOLONE CGAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240018138-A1 | PYRIDO[4,3-b]INDOLE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | VENTUS THERAPEUTICS U.S., INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240018138-A1 | PYRIDO[4,3-b]INDOLE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | VENTUS THERAPEUTICS U.S., INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240018138-A1 | PYRIDO[4,3-b]INDOLE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | VENTUS THERAPEUTICS U.S., INC. | 2024-01-18 | — | — | US | disclosed |
| WO-2023235809-A1 | CGAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2023-12-07 | — | — | WO | disclosed |
| US-20230391786-A1 | cGAS INHIBITORS | ELI LILLY AND COMPANY | 2023-12-07 | — | — | US | disclosed |
| WO-2023183275-A1 | HEXAHYDROPYRIDO[4,3-B]INDOLYL KETONE DERIVATIVES USEFUL AS CGAS MODULATORS | VENTUS THERAPEUTICS U.S., INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023183275-A1 | HEXAHYDROPYRIDO[4,3-B]INDOLYL KETONE DERIVATIVES USEFUL AS CGAS MODULATORS | VENTUS THERAPEUTICS U.S., INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| EP-4216940-A1 | PYRIDO[4,3-B]INDOLE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | Ventus Therapeutics U.S., Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116209442-A | Pyrido [4,3-b ] indole derivatives and their use as medicaments | 万特斯治疗美国公司 | 2023-06-02 | — | — | CN | disclosed |
| WO-2022066851-A1 | PYRIDO[4,3-b]INDOLE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | VENTUS THERAPEUTICS U.S., INC. (US) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179079-A1 | HEXAHYDROPYRIDO[4,3-B]INDOLYL KETONE DERIVATIVES USEFUL AS CGAS MODULATORS | CGAS, XDH, NPY1R | GPR35 2138/4885NMT1 3991/4885ALDH1A1 1205/4885 |
| US-20240018138-A1 | PYRIDO[4,3-b]INDOLE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | CGAS, LRRK2, ADSS2 | GPR35 1032/4885NMT1 2224/4885ALDH1A1 1142/4885 |
| US-20230391786-A1 | cGAS INHIBITORS | CGAS, STING1, TBK1 | GPR35 3259/4885NMT1 1690/4885ALDH1A1 4135/4885 |
| US-20240246979-A1 | cGAS INHIBITORS | CGAS, STING1, IRF3 | GPR35 2979/4885NMT1 1348/4885ALDH1A1 4299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.